Boon D M, Kappers-Klunne M C, Michiels J J, Stibbe J, van Vliet H H
Department of Haematology, University Hospital Dijkzigt, Erasmus University, Rotterdam, Netherlands.
Neth J Med. 1995 Mar;46(3):146-52. doi: 10.1016/0300-2977(94)00064-g.
Heparin-induced thrombocytopenia (HIT) is a severe complication of heparin therapy. Life-threatening thromboembolism (HITT) may occur in a large number of patients with HIT. In this article diagnostic problems and the clinical course of 4 typical patients are described. Diagnosis was based on the occurrence of thrombocytopenia during heparin therapy and was confirmed in vitro by an ELISA to heparin-platelet factor 4 antibodies, heparin-induced platelet activation assay (HIPAA) or the platelet aggregation assay (PAA). Thrombotic complications developed in 2 patients, one of whom suffered a fatal embolism after accidentally rechallenging with low-dose heparin which was used to maintain the patency of an intravascular catheter. After discontinuation of heparin the thrombocyte count rapidly increased to normal values during treatment with the heparinoid danaparoid (Orgaran) without complications.
肝素诱导的血小板减少症(HIT)是肝素治疗的一种严重并发症。大量HIT患者可能发生危及生命的血栓栓塞(HITT)。本文描述了4例典型患者的诊断问题及临床病程。诊断基于肝素治疗期间血小板减少的发生,并通过酶联免疫吸附测定法检测肝素 - 血小板因子4抗体、肝素诱导的血小板激活试验(HIPAA)或血小板聚集试验(PAA)在体外得以证实。2例患者出现血栓并发症,其中1例在意外再次使用低剂量肝素(用于维持血管内导管通畅)后发生致命栓塞。停用肝素后,在使用类肝素药物达那肝素(Orgaran)治疗期间血小板计数迅速升至正常水平,且无并发症发生。